Sp397
MAGNETIC RESONANCE AND ARTIFICIAL INTELLIGENCE IN LIVER DISEASE
Date
May 7, 2023
Explore related products in the following collection:
Society: AGA
Over the past decade, big data and artificial intelligence (AI) have become standard concepts in digestive disease research, both as individual tools and applied together. Artificial intelligence algorithms and large datasets are now applied to everything from unraveling the pathophysiology of disease mechanisms in model systems to precisely selecting the most appropriate treatment courses for patients. Speakers in this session will provide examples where big data and artificial intelligence have successfully advanced science and patient care, where these tools have failed to live up to expectations, and provide perspective on overcoming obstacles to further developing the tools. The session will focus on three thematic areas where AI and big data impact GI: clinical databases and natural language processing, biological datasets, and imaging.
Over the past decade, big data and artificial intelligence (AI) have become standard concepts in digestive disease research, both as individual tools and applied together. Artificial intelligence algorithms and large datasets are now applied to everything from unraveling the pathophysiology of disease mechanisms in model systems to precisely selecting the most appropriate treatment courses for patients. Speakers in this session will provide examples where big data and artificial intelligence have successfully advanced science and patient care, where these tools have failed to live up to expectations, and provide perspective on overcoming obstacles to further developing the tools. The session will focus on three thematic areas where AI and big data impact GI: clinical databases and natural language processing, biological datasets, and imaging.
Presenter
Mayo Clinic
Tracks
Related Products
PLACEHOLDER
Switching from originator to biosimilar infliximab (IFX) is effective and safe. However, data on multiple switching are scarce. The Edinburgh IBD unit has undertaken three switch programmes: (1) Remicade to CT-P13 (2016), (2) CT-P13 to SB2 (2020), and (3) SB2 to CT-P13 (2021)…
A PHASE 2, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL OF PRA023 AS INDUCTION THERAPY IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS: ARTEMIS-UC, COHORT 1
Switching from originator to biosimilar infliximab (IFX) is effective and safe. However, data on multiple switching are scarce. The Edinburgh IBD unit has undertaken three switch programmes: (1) Remicade to CT-P13 (2016), (2) CT-P13 to SB2 (2020), and (3) SB2 to CT-P13 (2021)…
HABITUAL MEAT INTAKE IS ASSOCIATED WITH INCREASED RISK OF DISEASE FLARE IN ULCERATIVE COLITIS: INITIAL RESULTS FROM THE PREDICCT STUDY
Switching from originator to biosimilar infliximab (IFX) is effective and safe. However, data on multiple switching are scarce. The Edinburgh IBD unit has undertaken three switch programmes: (1) Remicade to CT-P13 (2016), (2) CT-P13 to SB2 (2020), and (3) SB2 to CT-P13 (2021)…
ENCAPSULATED MICROBIOTA TRANSPLANT THERAPY IMPROVES PARTIAL MAYO SCORES IN ULCERATIVE COLITIS AND INDUCES RAPID ENGRAFTMENT COMPARED TO PLACEBO CONTROL
Switching from originator to biosimilar infliximab (IFX) is effective and safe. However, data on multiple switching are scarce. The Edinburgh IBD unit has undertaken three switch programmes: (1) Remicade to CT-P13 (2016), (2) CT-P13 to SB2 (2020), and (3) SB2 to CT-P13 (2021)…
